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President, 
Distinguished Delegates, 
Ladies and Gentleman, 
 
Last year I reminded the General Assembly that over 500,000 women die in childbirth 
or from complications of pregnancy every year. Every minute - one death. 95% of 
those dying are either African or Asian. 
 
Most of these maternal deaths are preventable. 
 
The scale of maternal mortality dwarfs the number of ‘disappearances’ and death 
penalty cases. Yet ‘disappearances’ and death penalty cases attract much more 
attention from the human rights community than preventable maternal mortality. 
‘Disappearances’, for example, have a UN human rights ‘special procedure’, as well 
as international and regional human rights treaties. And so they should. 
‘Disappearances’ are an extremely serious human rights issue. But so is preventable 
maternal mortality with its impact upon women’s rights to life, health, equality and 
non-discrimination. And yet there is not a single human rights mechanism with a 
focus on the immense problem of preventable maternal deaths. 
 
Since I raised these issues with you last year, UNFPA, the European Union and the 
University of Essex have produced a publication which looks at maternal mortality 
through the right-to-health lens.
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Last week a major, high-level and successful global conference on maternal health 
took place in London. Human rights were one of the themes recurring - intermittently 
- during the conference. 
 
The conference saw the launch of a new International Initiative on Maternal 
Mortality and Human Rights.
4
 Thoraya Obaid, the Executive Director of UNFPA, 
Mary Robinson, former UN High Commissioner for Human Rights, and others, spoke 
at the launch. 
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 On the occasion of the presentation of the report A/62/214, dated 8 August 2007. 
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 For convenience, I use ‘the right to health’ or ‘the right to the highest attainable standard of health’ as 
a shorthand for the full formulation of the right as set out in article 12(1) International Covenant on 
Economic, Social and Cultural Rights. 
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Right to the Highest Attainable Standard of Health, UNFPA/EU/University of Essex, 2007. 
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 For information about the Initiative, contact mstoffregen@reprorights.org 
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Driven by civil society, this Initiative aims to highlight the human rights catastrophe 
of maternal mortality. It aims to use human rights to strengthen - to reinforce – the 
existing commendable efforts to reduce maternal mortality and to promote 
functioning health systems. It aims to encourage maternal health workers to use 
human rights analysis, advocacy and networks to further their goals. 
 
The Initiative is a challenge to both developed and developing countries. When data 
in developed countries are disaggregated, they often reveal that maternal mortality 
among minorities and indigenous communities is significantly higher than among 
dominant groups. Also, developed countries have a human rights responsibility - 
reflected in Millennium Development Goals 5 and 8 – to take reasonable measures to 
address maternal mortality in developing countries. 
 
I am pleased to report that the Government of India has invited me to undertake a 
formal mission in November to look at maternal mortality. This mission will enable 
me to explore, in detail, the practical contribution that the right to health can make in 
our collective struggle against preventable maternal deaths. 
 
Still, there is much more to be done to ensure that maternal mortality receives the 
human rights attention it deserves. 
 
Here, the Human Rights Council can play a leadership role. 
 
I recommend that the Council convenes a Special Session on maternal mortality. The 
key UN agencies could be invited to offer their insights and expertise. States could 
share their good practices. 
 
This would be a unique opportunity for the Council to tell the world that preventable 
maternal mortality is a human rights issue of enormous gravity. Of course, human 
rights do not provide magic solutions to the global problem of maternal mortality. But 
human rights have a practical contribution to make. These are among the vital 
messages that a Special Session could convey. 
 
Most importantly, a Special Session could save women’s lives and reduce suffering. 
 
Water and sanitation 
The right to the highest attainable standard of health is more than a right to medical 
care. Additionally, it extends to the pre-conditions of health, also known as the 
underlying determinants of health.
5
 There are many underlying determinants of 
health, including access to safe water, adequate sanitation, an adequate supply of safe 
food and nutrition, freedom from discrimination, to name but a few. 
 
Unfortunately, there is a definite tendency among some Governments and 
international organisations to devote a disproportionate amount of attention and 
resources to medical care, at the expense of the underlying determinants of health. 
This is deeply regrettable because both are fundamental, inter-related elements of the 
right to the highest attainable standard of health. 
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 See, for example, article 12 International Covenant on Economic, Social and Cultural Rights and 
article 24 Convention on the Rights of the Child.  
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My present report to the General Assembly focuses on two underlying determinants 
of health: access to safe water and adequate sanitation.
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Access to improved water and sanitation would save millions of lives and reduce 
terrible suffering. It would reduce malaria, diarrhoeal diseases, including cholera, 
blindness from trachoma, and so on. It would also bring substantial economic 
benefits. According to WHO, each dollar invested would yield an economic return of 
between $3 and $34, depending upon the region. 
 
My report analyses water and sanitation through the prism of the right to the highest 
attainable standard of health. I will not repeat that analysis here but emphasise the 
inadequacy of many States’ water and sanitation policies, programmes and laws. 
 
States should recognise that the right to the highest attainable standard of health 
includes access to safe water and adequate sanitation. Measures to enhance access to 
safe water and sanitation must give particular attention to disadvantaged groups and 
individuals. It is extremely important that water and sanitation policies are gender-
sensitive. Large-scale public awareness health campaigns are needed to provide 
information on hygiene and safe water storage. Many States have yet to put in place 
effective monitoring and accountability mechanisms in relation to water and 
sanitation. 
 
Global warming is a serious obstacle to the right to the highest attainable standard of 
health. It has led to a decline in dependable access to water, as well as disruption to 
natural ecosystems. Warmer and wetter conditions are increasing the range of 
mosquitoes, tsetse flies and other vectors which spread tropical diseases like malaria 
and yellow fever. As clean water sources evaporate, people resort to polluted 
alternatives that lead to ill-health. People living in poverty are disproportionately 
affected by the adverse effects of global warming. The international community has a 
duty to recognise and confront the health threats posed by global warming. 
 
I recommend that the Human Rights Council undertake, as soon as possible, a study 
that looks at the impact of climate change on human rights, including the right to the 
highest attainable standard of health. 
 
Impact assessments 
A human rights impact assessment is a process for predicting the likely impact of a 
proposed policy, or other initiative, on the enjoyment of human rights. If the 
assessment finds that the human rights impact is likely to be negative, the 
Government then has an opportunity to revise and improve the proposed policy before 
it is finalised and implemented.
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Without an appropriate impact assessment methodology, a Government cannot know 
whether its proposed initiatives are on target to progressively realise the right to the 
highest attainable standard of health, as required by international human rights law. 
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 Chapters IV and V. 
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 In my first report to the Commission on Human Rights, I signalled my intention to look at the issue of 
impact assessments. The Commission responded by passing a resolution expressly encouraging me to 
pursue this analysis. 
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From the right to health perspective, an impact assessment methodology is a key 
feature of a health system. 
 
In 2006, I co-authored a report on impact assessments and the right to the highest 
attainable standard of health.
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 I am very grateful to UNESCO for funding this 
research. This co-authored study introduces a human rights impact assessment 
methodology, with a particular focus on the right to the highest attainable standard of 
health. 
 
The study is outlined in my present report to the General Assembly.
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Neglected diseases 
In my first report to the Commission on Human Rights, I signalled my intention to 
look at the issue of neglected diseases. The Commission responded by passing a 
resolution expressly encouraging me to pursue this analysis. 
 
By neglected diseases I mean those diseases mainly afflicting the poorest people in 
the poorest countries, such as river blindness, sleeping sickness and lymphatic 
filariasis. According to WHO, almost 1 billion people suffer from severe and 
permanent disabilities and deformities arising from neglected diseases. 
 
The introduction of basic public health measures, such as access to clean water and 
sanitation, would significantly reduce the burden of several neglected diseases. Where 
medical interventions exist, they generally fail to reach those populations in greatest 
need. History shows that the development of new drugs and vaccines for neglected 
diseases has been under-funded, largely because there has been little or no market 
incentive. In the last few years, however, some pharmaceutical companies deserve 
credit for taking active steps to redress this historic neglect and imbalance. 
 
In 2006, I undertook a formal mission, in cooperation with WHO, to Uganda and my 
report looked exclusively at neglected diseases. Although the report focuses on 
Uganda, much of its analysis and many of its recommendations have application to 
the many States whose people suffer from neglected diseases.
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I am pleased to report that a few weeks ago a study was published called Neglected 
Diseases: A Human Rights Analysis which I co-authored with three colleagues.
11
 The 
report was published by the Special Programme for Research and Training in Tropical 
Diseases (known as ‘TDR’), which is sponsored by WHO, UNICEF, UNDP and the 
World Bank. TDR also provided financial support for the necessary research -- I am 
most grateful to TDR for its extraordinary support. I am also very grateful to OHCHR 
and WHO for their contributions to this project. 
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 My co-author is Gillian MacNaughton, to whom I am most grateful. Impact assessments, poverty and 
human rights: A case study using the right to the highest attainable standard of health, UNESCO, 
2006. The report is available from the website of Essex University, Human Rights Centre, Right to 
Health Unit www2.essex.ac.uk/human_rights_centre/rth/projects.shtm 
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 In 2007, I undertook a follow-up mission to Uganda. In 2004, I undertook a formal mission to the 
World Trade Organisation, neglected diseases being one of the issues my report focused on. 
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 My co-authors are Rebecca Steward, Judith Bueno de Mesquita and Lisa Oldring, to whom I am 
most grateful. Neglected diseases: A human rights analysis, TDR, 2007. 
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When read together, the TDR publication and the Ugandan report provide a practical 
introduction to neglected diseases and human rights. Together they show that the right 
to the highest attainable standard of health is not mere rhetoric, but a practical tool 
that can contribute to good policy making. 
 
Draft Human Rights Guidelines for Pharmaceutical Companies in relation to Access 
to Medicines 
Last year, my report to the General Assembly included a chapter on the human right 
to medicines. States have primary responsibility for enhancing access to medicines 
and so most of my report looked at States’ duties. But the report also looked at the 
responsibilities of pharmaceutical companies in relation to access to medicines. 
 
The report identified some major questions. What, precisely, are the human rights 
responsibilities of pharmaceutical companies in relation to access to medicines? How 
can we expect pharmaceutical companies to respect human rights if it is not clear 
what is required of them? 
 
The report explained that I had embarked on a process of preparing draft Guidelines 
for pharmaceutical companies in relation to access to medicines; the draft was an 
attempt to respond to these major questions. Last year, in the interactive dialogue with 
the Third Committee, I was encouraged to proceed with this challenging project. 
 
I am pleased to report that I have now prepared, for consultation, draft Human Rights 
Guidelines for Pharmaceutical Companies in relation to Access to Medicines.
12
 The 
draft was made available for public comment in mid-September 2007, following a 
multi-stakeholder workshop at the University of Toronto. Pharmaceutical companies 
participated at this workshop. 
 
The draft is available for comment until 31 December 2007. I am now actively 
canvassing the comments of various stakeholders, including pharmaceutical 
companies. Next month, for example, I will discuss the draft with the International 
Federation of Pharmaceutical Manufacturers and Associations. I will also be meeting 
some pharmaceutical companies on a bilateral basis. 
 
The draft Guidelines address some key access-to-medicines issues, such as research 
and development for neglected diseases, pricing, ethical marketing, clinical trials, and 
corruption. 
 
A commentary makes the link between the selected issues and the right to the highest 
attainable standard of health. Then forty-eight draft guidelines are put on the table for 
comment. 
 
May I emphasise that the draft does not proceed on the basis that pharmaceutical 
companies are legally bound by international human rights law. Nor does the draft use 
the peremptory word “must”. Rather, it uses the much more modest language 
“should”. In other words, I have deliberately avoided the most controversial doctrinal 
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Right to Health Unit www2.essex.ac.uk/human_rights_centre/rth/projects.shtm 
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issues that have plagued debates about business corporations and human rights for 
many years. 
 
Instead, I have tried to be practical and constructive, and sought to apply the right to 
the highest attainable standard of health to the very specific domain of pharmaceutical 
companies and access to medicines. 
 
Since my appointment in 2002, I have met with pharmaceutical companies on 
numerous occasions and have closely discussed with them the issues that form the 
core of the draft Guidelines. These discussions have been extremely helpful and they 
have profoundly influenced my draft. Some of these discussions have been in the 
form of day-long consultations organised by Realizing Rights: The Ethical 
Globalization Initiative, led by Mary Robinson. Others have been during visits to 
pharmaceutical companies. 
 
In a series of substantive meetings with a number of major pharmaceutical companies, 
Mrs Robinson and I put forward a two-phase proposal. The proposal was discussed at 
length with the companies and revised to accommodate a number of their concerns. 
 
First, we suggested that a small group of human rights experts, and representatives 
from pharmaceutical companies, work together to identify as much common ground 
as possible, as well as good faith disagreements, in relation to access to medicines. 
We envisaged this would take two years and would generate an important, useful 
report that began to clarify what can properly be asked of pharmaceutical companies 
in relation to access to medicines and human rights. 
 
Second, a small group of experts would then be appointed, by consensus among those 
participating in the initiative, to use this report to evaluate the policies and practices of 
certain pharmaceutical companies. These evaluations would be made public. We 
envisaged this second phase would last for an initial period of three years. 
 
The hallmark of our two-phase, five-year proposal was constructive cooperation and 
collaboration with a number of major pharmaceutical companies. 
 
To their considerable credit, two companies, Novartis and NovoNordisk, were willing 
to proceed with the proposal. Unfortunately, however, the majority of companies 
involved in the initiative were not willing to go-ahead. Reluctantly, Mrs Robinson and 
I decided that buy-in from only two companies was insufficient for what was 
designed to be a collaborative initiative engaging a range of major pharmaceutical 
companies.  Accordingly, we felt we had no alternative but to put the proposal aside. 
 
But the work still needs to be done. 
 
I hope the Guidelines - after extensive consultations - will clarify what can reasonably 
be expected of pharmaceutical companies in relation to access to medicines and the 
right to the highest attainable standard of health. 
 
Of course, I have sole responsibility for the draft Guidelines and will have sole 
responsibility for the final version. 
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May I again emphasise that States have primary responsibility for enhancing access to 
medicines. So far, in my access-to-medicines work, I have given priority to 
consideration of this State responsibility. My 2006 report to the General Assembly 
includes a detailed chapter setting out these State duties. Over the last five years, 
when on country mission, I have held States to account in relation to their right to 
health duties and access to medicines. Drawing on this experience - and if my 
resources permit – I hope to prepare, in collaboration with treaty-body and other 
experts, some draft Guidelines for States in relation to access to medicines. 
 
Now, however, it is time to look more closely at the human rights duties of 
pharmaceutical companies in relation to access to medicines. 
 
Regarding the draft Guidelines for pharmaceutical companies, all comments will be 
most welcome before the end of this year. 
 
My aim is to finalise these Guidelines in 2008. 
 
***** 
